PREDICTION OF RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN HEPATITIS C PATIENTS BY IL28B VARIATION AND ITS RELATION TO OTHER DIFFERENT PREDICTORS.

  • Assistant lecturer of internal medicine, Kasr Alainy, Cairo University.
  • Lecturer of internal medicine, Kasr Alainy, Cairo University.
  • Prof. of biochemistry, Kasr Alainy, Cairo University.
  • Prof. of internal medicine, Kasr Alainy, Cairo University.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Worldwide, hepatitis C Virus (HCV) is recognized as a major threat to global public health. Accurately predicting the patients who will respond to therapy of HCV by interferon and ribavirin is still important, for patient care and also with respect to the cost as new DAAs are not always available. Studies have shown that IL28B is strongly associated with the response to treatment of hepatitis C by interferon and ribavirin. Our patients are 200 divided into two equal groups, responders and non- responders to Interferon ribavirin treatment. They are submitted to detailed history and clinical examination including body mass index calculation, laboratory examination: CBC, PT, PC, serum Albumin, AST, ALT, Bilirubin total, viral load by PCR , abdominal ultrasound , liver biopsy, IL28B gene. We proved that IL28B is the strongest predictor of response of treatment by Peg/interferon ribavirin and CC allele has the best chance to respond to treatment. Also, BMI, ALT and ALP could be used as predictors for response.

  1. AS Hgar H et al, Helmy H ,Khan M. Predictors of sustained virologic response at course of 48 week of treatment by PEG interferon alpha 2a and ribavirin in patients infected by HCV genotype 4 . Ann Saudi Med 2009; 29 (1):4-14.
  2. Asselah T, De Muynck S, Bro?t P?et al., IL28B?polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.?J Hepatol2012; 56: 527?532.
  3. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, et al. (2003) Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology2003; 37(3): 600?609.
  4. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for non-response to antiviral treatment in chronic Hepatitis C. Hepatology2003; 38: 639-644.
  5. Butti M treatment de la hepatitis corinica c. Factors relacionados con la respuesta. GH continuada2002; 1: 2.
  6. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ribavirin.?Aliment Pharmacol Ther2012; 36: 91?103.
  7. Conjeevaram H.S., Fried M.W., Jeffers L.J., Terrault N.A., Wiley-Lucas T.E., Afdhal N. et al. (2006) Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470?477.
  8. De Nicola S, Aghemo A, Rumi MG?et al.?An?IL28B?polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.?Hepatology2012; 55: 336?342.
  9. Ekram W. Abd El-Wahab, Ashraf Mikheal, Fathallah Sidkey and Hanan Z. Shatat. Insulin Resistance as a Predictor of Early Virologic Response to HCV Therapy Among Chronic HCV Egyptian Patients. Journal of Medical Virology2015; 87: 428?440.
  10. El-Zanaty F, Way A. Egypt Demographic and Health Survey 2008. Egyptian: Ministry of Health. El-Zanaty and Associates, and Macro International. Cairo. p 431, 2009. Egypt Demographic Health Survey: Final Report - June 2009.
  11. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB:?Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature?2009;?461(7262): 399-401.
  12. Gmal El Din Esmat Gamil, Maissa El Said El Raziky, Rabab Maamoun Salama, Wafaa Ahmed El Akel, Waleed Fouad Fathalah1, Dina Ismail Attia? ?Factors Associated with Rapid and Early Virologic Response to Peginterferon Alfa- 2a/Ribavirin Treatment in HCV Genotype 1 Patient?s Representative of the General Chronic Hepatitis C Population,? Journal of Viral Hepatitis2010; Vol. 17, No. 2, pp. 139-147.
  13. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al., Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. Mar 2 2004; 140(5): 346-55.
  14. Henk Bekedam, Egypt steps up efforts against hepatitis C WHO July 2014.
  15. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J. Hepatol. 2008; 49(4), 634?651.
  16. Lavanchy D. Evolving epidemiology of hepatitis C virus.?Clin Microbiol Infect?2011; 17: 107?115.
  17. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51:1122?6.
  18. Muhammad Idrees and Sheikh Riazuddin. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterology 2009; 9: 5.
  19. Pineda JA, Caruz A, Rivero A?et al.,?Prediction of response to pegylated interferon plus ribavirin by?IL28B?gene variation in patients coinfected with HIV and hepatitis C virus.?Clin. Infect Dis2010; 51: 788?795.
  20. Rall?n NI, Soriano V, Naggie S?et al., IL28B?gene polymorphisms and viral kinetics in HIV/hepatitis C virus- coinfected patients treated with pegylated interferon and ribavirin.?AIDS?2011; 25: 1025?1033.
  21. Scherzer TM, Hofer H, Staettermayer AF?et al.,?Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.?J Hepatol?2011; 54: 866?871.
  22. St?ttermayer AF, Stauber R, Hofer H?et al.,?Impact of?IL28B?genotype on the early and sustained virologic response in treatment-na?ve patients with chronic hepatitis C.?Clin Gastroenterol Hepatol2011; 9: 344?350.
  23. Strickland GT et al., 2002 Strickland GT, et al. 2002. Role of hepatitis C infection in chronic liver disease in Egypt. Am. J. Trop. Med. Hyg. 67:436?442.
  24. Thomas DL, Thio CL, Martin MP?et al.,?Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.Nature2009; 461: 798?801.
  25. Thompson AJ, Muir AJ, Sulkowski MS?et al.,?Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.?Gastroenterology2010; 139: 120?129.
  26. Yu ML, 2008 23.Yu ML et al. (2008) Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 47: 1884?1893.
  27. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004 Jun; 40(6):993-9.
  28. Zeuzem S, Rodrguez-Torres M, Rajender Reddy K, Marcellin P, Diago M, et al. (2012) Optimized threshold for serum HCV RNA to predict treatment outcomes in Hepatitis C patients receiving peginterferon alfa-2a/ribavirin or in population with recurrent HCV genotype 1 infection after living donor liver transplantation. J Viral Hepat2012; 19: 766-774.

[Noran Atef Elkordy, Ahmed Yamani Sayed, Dina Sabry Abd Elfatah, Mona Ahmed Amin, Ali Hassan Farag and Dina Abd Elhakeem Elgendy. (2017); PREDICTION OF RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN HEPATITIS C PATIENTS BY IL28B VARIATION AND ITS RELATION TO OTHER DIFFERENT PREDICTORS. Int. J. of Adv. Res. 5 (Mar). 2172-2178] (ISSN 2320-5407). www.journalijar.com

NoranAtef Elkordy

DOI:

Article DOI: 10.21474/IJAR01/3736      
DOI URL: https://dx.doi.org/10.21474/IJAR01/3736

Download Full Paper

Download PDF No. of Downloads: 5 | No. of Views: 75